Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia

Journal of Pharmacy and Pharmacology

Volumn 54, Issue 12, 2002, Pages 1693-1696

  Jaruratanasirikul, Sutep ^a   Sriwiriyajan, Somchai ^a   Ingviya, Natnicha ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFADROXIL; CEFEPIME;

ADULT; ARTICLE; BACTERIUM ISOLATE; BLOOD SAMPLING; BOLUS INJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE SEPSIS; HUMAN; MALE; MICROBIAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POWDER; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; AREA UNDER CURVE; CEPHALOSPORINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG STABILITY; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 0036912702     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/002235702171     Document Type: Article

References (14)

1. Barbhaiya, R. H., Forgue, S. T., Shyu, W. C., Papp, E. A., Pittman, K. A. (1987) High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine. Antimicrob. Agents Chemother. 31: 55-59
2. Barradell, L. B., Bryson, H. M. (1994) Cefepime: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 47: 471-505
3. Benko, A. S., Cappelletty, D. M., Kruse, J. A., Rybak, M. J. (1996) Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected Gram-negative infections. Antimicrob. Agents Chemother. 40: 691-695
4. Burgess, D. S., Hastings, R. W., Hardin, T. C. (2000) Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clin. Ther. 22: 66-75
5. Craig, W. A. (1995) Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22: 89-96
6. Craig, W. A., Ebert, S. C. (1992) Continuous infusion of β-lactam antibiotics. Antimicrob. Agents Chemother. 36: 2577-2583
7. Lipman, J., Gomersall, C. D., Gin, T., Joynt, G. M., Young, R. J. (1999) Continuous infusion ceftazidime in intensive care: A randomized controlled trial. J. Antimicrob. Chemother. 43: 309-311
8. Livingston, D. H., Wang, M. T. (1993) Continuous infusion of cefazolin is superior to intermittent dosing in decreasing infection after hemorrhagic shock. Am. J. Surg. 165: 203-207
9. Mordenti, J. J., Quintiliani, R., Nightingale, C. H. (1985) Combination antibiotic therapy: Comparison of constant infusion and intermittent bolus dosing in an experimental animal model. J. Antimicrob. Chemother. 15 (suppl. A): 313-321
10. Mouton, J. W., Den Hollander, J. G. (1994) Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 38: 931-936
11. Nicolau, D. P., Quintiliani, R. (1994) Choosing among the new cephalosporin antibiotics: A pharmacodynamic approach. Pharmacoeconomics 5 (suppl. 2): 34-39
12. Nicolau, D., Quintiliani, R., Nightingale, C. H. (1992) Once-daily aminoglycosides. Conn. Med. 56: 561-563
13. Nicolau, D. P., Nightingale, C. H., Benevicius, M. A., Fu, Q., Quintiliani, R. (1996) Serum bactericidal activity of ceftazidime: Continuous infusion versus intermittent injections. Antimicrob. Agents Chemother. 40: 61-64
14. Vogelman, B., Gudmundsson, S., Leggett, J., Turnidge, J., Ebert, S., Craig, W. A. (1988) Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis. 158: 831-847